Exhibit 99.1

STERIS CORPORATION ANNOUNCES FISCAL 2012 THIRD QUARTER RESULTS

Mentor, Ohio (February 7, 2012)—STERIS Corporation (NYSE: STE) today announced financial results for its fiscal 2012 third quarter ended December 31, 2011. As reported, fiscal 2012 third quarter revenue grew 8% to $355.2 million compared with $328.3 million in the third quarter of fiscal 2011 with growth in all three business segments.

As reported, fiscal 2012 third quarter net income was $33.6 million, or $0.58 per diluted share, compared with $21.8 million, or $0.36 per diluted share in the third quarter of fiscal 2011. During the third quarter of fiscal 2011 the Company recorded a pre-tax charge of $19.8 million ($13.1 million or $0.22 per diluted share after tax) for the settlement of the SYSTEM 1^® class action litigation. In addition, fiscal 2011 third quarter net income was impacted favorably in the amount of $0.01 per diluted share due to a tax rate benefit from the previously announced SYSTEM 1 Rebate Program. Please see the attached schedules for more information, including comparisons which exclude the impact of the SYSTEM 1 Rebate Program, class action litigation and restructuring.

“We are pleased with the solid revenue growth and free cash flow generation in our third quarter. However, profitability was dampened due to product mix and certain investments continuing to be made for the long-term benefit of the Company,” said Walt Rosebrough, President and Chief Executive Officer of STERIS. “In the fourth quarter, we anticipate a modest decline in revenue year over year as we have tough comparisons in both Healthcare and Life Sciences. In addition, we anticipate that our long-term investments in the business will continue at a higher rate than our previous estimate. As a result, we now anticipate that our full year, total Company revenue growth will be approximately 6%, with earnings per diluted share in the range of $2.13 to $2.20.”

Segment Results

Healthcare revenue in the quarter increased 9% to $259.1 million compared with $237.8 million in the third quarter of fiscal 2011. Revenue growth was driven by 22% growth in capital equipment offset by a 7% decline in consumable revenue and a 1% decrease in service revenue. As reported, operating income was $34.0 million compared with $20.4 million in last year’s third quarter. Adjusting for the impact of the SYSTEM 1^® class action litigation charge, Healthcare operating income for the third quarter of fiscal 2011 would have been $40.2 million. The decline in operating income year over year was due to a reduction in gross margin, costs associated with consolidation efforts and investments made to improve product reliability.

Life Sciences third quarter revenue increased 9% to $55.9 million compared with $51.2 million in the third quarter of fiscal 2011. Revenue growth was driven by a 25% increase in capital equipment and 4% growth in consumables, slightly offset by a 1% decline in service revenue.

Life Sciences operating income was $10.3 million compared with $7.3 million in the third quarter last year. The increase in operating income was primarily a result of the higher volumes.

Fiscal 2012 third quarter revenue for Isomedix Services was $39.6 million compared with $38.1 million in the same period last year, an increase of 4%. Operating income was $11.8 million in the quarter compared with $10.3 million in the third quarter of last year, driven primarily by increased efficiencies in the business.

Cash Flow

Net cash provided by operations for the first nine months of fiscal 2012 was $112.8 million, compared with $83.4 million in the same period last year. Free cash flow (see note 1) for the first nine months of fiscal 2012 was $58.6 million, compared with $28.3 million in the prior year. The increase in free cash flow is primarily related to improvements in working capital requirements.

During the quarter, the Company repurchased just over 347,000 shares of its common stock at an average price of $28.81 per share for a total amount of $10.0 million. Through the first nine months of fiscal 2012, the Company has repurchased approximately 1.9 million shares at an average price of $30.21 per share for a total amount of $56.0 million. Approximately $118 million remains available for additional purchases under the current share repurchase authorization.

Dividend Announcement

The Company also announced today that STERIS’s Board of Directors has authorized a quarterly dividend of $0.17 per common share. The dividend is payable March 27, 2012 to shareholders of record at the close of business on February 28, 2012.

Outlook

Based upon year-to-date performance and current trends, the Company now expects fiscal 2012 revenue growth to be approximately 6% and earnings per diluted share in the range of $2.13 to $2.20 for the full fiscal year. This compares with prior expectations of 8-10% revenue growth and earnings per diluted share of $2.25 to $2.45. This outlook reflects certain key assumptions, some of which are listed below:

For the full fiscal year 2012, free cash flow (see note 1) is anticipated to be approximately $110 million excluding the payments related to the SYSTEM 1 Rebate Program and class action litigation settlement, or $90 million as reported including those items. Capital expenditures are anticipated to be approximately $70 million.

Conference Call

In conjunction with this release, STERIS Corporation management will host a conference call today at 10:00 a.m. Eastern time. The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1-800-369-8428 in the United States and Canada, and 1-773-799-3378 internationally, then referencing the password “STERIS”. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. Eastern time today, either over the Internet at www.steris-ir.com or via phone by calling 1-866-395-9179 in the United States and Canada, and 1-203-369-0503 internationally.

About STERIS

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company has approximately 5,000 dedicated employees around the world working together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government Customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.

This news release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,”

“deliver,” “comfortable,” “trend”, and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or interpretation thereof. Other risk factors are described herein and in the Company’s Form 10-K and other securities filings. Many of these important factors are outside STERIS’s control. No assurances can be provided as to any result or the timing of any outcome regarding matters described in the referenced release or conference call or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, rebate program, transition, cost reductions, business strategies, earnings or revenue trends or future financial results (including without limitation the settlement of the SYSTEM 1 class action litigation and the regulatory submission for the SYSTEM 1E indicator). References to products, the consent decree, the transition or rebate program, or the class action settlement, are summaries only and do not alter or modify the specific terms of the decree, settlement, program or product clearance or literature. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing or costs that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications or the Company’s rebate program, transition plan or other business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation those relating to FDA warning letters, government investigations, the December 3, 2009 or February 22, 2010 FDA notices, the April 20, 2010 consent decree and related transition plan and rebate program, the SYSTEM 1E device, the outcome of any pending FDA requests and submissions, or other requirements or standards may delay, limit or prevent new product introductions, affect the production and marketing of existing products or services or otherwise affect Company performance, results, prospects or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or anticipated rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company’s products and services, (f) the possibility that anticipated growth, cost savings, rebate assumptions, new product acceptance, performance or approvals, including without limitation SYSTEM 1E and accessories thereto, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with our business, industry or initiatives including, without limitation, the consent decree, rebate program, and the transition from the SYSTEM 1 processing system or those matters described in our Form 10-K for the year ended March 31, 2011 and other securities filings, may adversely impact company performance, results, prospects or value, (g) the effect of the contraction in credit availability, as well as the ability of our Customers and suppliers to adequately access the credit markets when needed, and (h) those risks described in our securities filings including our Annual Report on Form 10-K for the year ended March 31, 2011, and other securities filings.

Contact: Julie Winter, Director, Investor Relations at 440-392-7245.

STERIS Corporation

Consolidated Condensed Statements of Operations

(In thousands, except per share data)

STERIS Corporation

Consolidated Condensed Balance Sheets

(In thousands)

STERIS Corporation

Segment Data

(In thousands)

STERIS Corporation

Consolidated Condensed Statements of Cash Flows

(In thousands)

The following table presents a financial measure which is considered to be "non-GAAP financial measures" under Securities Exchange Commission rules. Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles, net (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles. The Company uses free cash flow as a measure to gauge its ability to fund future principal debt repayments, growth outside of core operations, repurchase common shares, and pay cash dividends. STERIS's calculation of free cash flow may vary from other companies.

STERIS Corporation

Unaudited Supplemental Financial Data

Third Quarter Fiscal 2012

As of December 31, 2011

This supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt.

STERIS Corporation

Non-GAAP Financial Measures

(In thousands, except per share data)

The Company has referred to certain adjusted financial measures regarding the results of operations excluding the SYSTEM 1 Rebate Program and related disposal costs and restructuring to provide meaningful comparative analysis between the periods. These financial measures are considered to be “non-GAAP financial measures” under Securities Exchange Commission rules. Reconciliation of each financial measure to its nearest GAAP financial measure is provided in the table below.